Blockbuster in the balance: Celgene's Reblozyl faces FDA committee for myelodysplastic syndromes

3rd December 2019 Uncategorised 0

In its final days as an independent company, Celgene scored a win last month with the FDA’s approval of rare blood disease med Reblozyl—a potential blockbuster in some analysts’ eyes. Now, the FDA wants a closer look at Reblozyl as a treatment for a group of rare blood cancers. 

More: Blockbuster in the balance: Celgene's Reblozyl faces FDA committee for myelodysplastic syndromes
Source: fierce